The effect of hormonal treatment on conspicuity of prostate cancer: Implications for focal boosting radiotherapy

Radiotherapy and Oncology

Volumn 103, Issue 2, 2012, Pages 233-238

  Groenendaal, Greetje ^a   Van Vulpen, Marco ^a   Pereboom, Susanne R ^a   Poelma Tap, Davey ^a   Korporaal, Johannes G ^a   Monninkhof, Evelyn ^a   Van Der Heide, Uulke A ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Androgen; DCE MRI; DWI; Tumor delineation

Indexed keywords

ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BRACHYTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER TISSUE; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; DYNAMIC CONTRAST ENHANCED MAGNETIC RESONANCE IMAGING; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROBABILITY; PROSTATE CANCER; RETROSPECTIVE STUDY; TREATMENT DURATION;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; BRACHYTHERAPY; DIFFUSION MAGNETIC RESONANCE IMAGING; HUMANS; IODINE RADIOISOTOPES; LOGISTIC MODELS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RADIOTHERAPY, INTENSITY-MODULATED; RETROSPECTIVE STUDIES;

EID: 84860490687     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2011.12.007     Document Type: Article

References (35)

1. N. Cellini, A.G. Morganti, and G.C. Mattiucci Analysis of intraprostatic failures in patients treated with hormonal therapy and radiotherapy: implications for conformal therapy planning Int J Radiat Oncol Biol Phys 53 2002 595 599
2. D. Pucar, H. Hricak, and A. Shukla-Dave Clinically significant prostate cancer local recurrence after radiation therapy occurs at the site of primary tumor: magnetic resonance imaging and step-section pathology evidence Int J Radiat Oncol Biol Phys 69 2007 62 69
3. B. Pickett, E. Vigneault, J. Kurhanewicz, L. Verhey, and M. Roach Static field intensity modulation to treat a dominant intra-prostatic lesion to 90 Gy compared to seven field 3-dimensional radiotherapy Int J Radiat Oncol Biol Phys 43 1999 921 929
4. E.N.J.T. Van Lin, J.J. Fütterer, and S.W.T.P.J. Heijmink IMRT boost dose planning on dominant intraprostatic lesions: gold marker-based three-dimensional fusion of CT with dynamic contrast-enhanced and 1H-spectroscopic MRI Int J Radiat Oncol Biol Phys 65 2006 291 303
5. A.K. Singh, P. Guion, and N. Sears-Crouse Simultaneous integrated boost of biopsy proven, MRI defined dominant intra-prostatic lesions to 95 Gray with IMRT: early results of a phase I NCI study Radiat Oncol 2 2007 36
6. R. Miralbell, M. Molla, and M. Rouzaud Hypofractionated boost to the dominant tumor region with intensity modulated stereotactic radiotherapy for prostate cancer: a sequential dose escalation pilot study Int J Radiat Oncol Biol Phys 78 2010 50 57
7. M.D. Pickles, P. Gibbs, M. Sreenivas, and L.W. Turnbull Diffusion-weighted imaging of normal and malignant prostate tissue at 30 T J Magn Reson Imaging 23 2006 130 134
8. P. Gibbs, M.D. Pickles, and L.W. Turnbull Diffusion imaging of the prostate at 3.0 tesla Invest Radiol 41 2006 185 188
9. V. Kumar, N.R. Jagannathan, and K. R Apparent diffusion coefficient of the prostate in men prior to biopsy: determination of a cut-off value to predict malignancy of the peripheral zone NMR Biomed 20 2007 505 511
10. C. Sato, S. Naganawa, and T. Nakamura Differentiation of noncancerous tissue and cancer lesions by apparent diffusion coefficient values in transition and peripheral zones of the prostate J Magn Reson Imaging 21 2005 258 262
11. K. Hosseinzadeh, and S.D. Schwarz Endorectal diffusion-weighted imaging in prostate cancer to differentiate malignant and benign peripheral zone tissue J Magn Reson Imaging 20 2004 654 661
12. J.J. Fütterer, S.W.T.P.J. Heijmink, and T.W.J. Scheenen Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging Radiology 241 2006 449 458
13. P. Kozlowski, S.D. Chang, E.C. Jones, K.W. Berean, H. Chen, and S.L. Goldenberg Combined diffusion-weighted and dynamic contrast-enhanced MRI for prostate cancer diagnosis-correlation with biopsy and histopathology J Magn Reson Imaging 24 2006 108 113
14. F.A. Van Dorsten, M. van der Graaf, and M.R.W. Engelbrecht Combined quantitative dynamic contrast-enhanced MR imaging an 1H MR spectroscopic imaging of human prostate cancer J Magn Reson Imaging 20 2004 279 287
15. A.R. Padhani Dynamic contrast-enhanced MR in clinical oncology: current status and future directions J Magn Reson Imaging 16 2002 407 422
16. D.L. Buckley, C. Roberts, G.J.M. Parker, J.P. Logue, and C.E. Hutchinson Prostate cancer: evaluation of vascular characteristics with dynamic contrast-enhanced T1-weighted MR imaging - initial experience Radiology 233 2004 709 715
17. G. Groenendaal, M.R. Moman, and J.G. Korporaal Validation of functional imaging with pathology for tumor delineation in the prostate Radiother Oncol 94 2010 145 150
18. G. Groenendaal, C.A.T. van den Berg, and J.G. Korporaal Simultaneous MRI diffusion and perfusion imaging for tumor delineation in prostate cancer patients Radiother Oncol 95 2010 185 190
19. J.G. Korporaal, C.A.T. van den Berg, G. Groenendaal, M.R. Moman, M. van Vulpen, and U.A. van der Heide The use of probability maps to deal with the uncertainties in prostate cancer delineation Radiother Oncol 94 2010 168 172
20. R. Alonzi, A.R. Padhani, and N.J. Taylor Antivascular effects of neoadjuvant androgen deprivation for prostate cancer: an in vivo human study using susceptibility and relaxivity dynamic MRI Int J Radiat Oncol Biol Phys 80 2010 721 727
21. A.R. Padhani, A.D. MacVicar, and C.J. Gapinski Effects of androgen deprivation on prostatic morphology and vascular permeability evaluated with MR imaging Radiology 218 2001 365 374
22. S.R. Denmeade, X.S. Lin, and J.T. Isaacs Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer Prostate 28 1996 251 265
23. J. Xu, P.A. Humphrey, and A.S. Kibel Magnetic resonance diffusion characteristics of histologically defined prostate cancer in humans Magn Reson Med 61 2009 842 850
24. P. Gibbs, G.P. Liney, M.D. Pickles, B. Zelhof, G. Rodrigues, and L.W. Turnbull Correlation of ADC and t2 measurements with cell density in prostate cancer at 3.0 tesla IR 44 2009 572 576
25. B. Zelhof, M. Pickles, and G. Liney Correlation of diffusion-weighted magnetic resonance data with cellularity in prostate cancer BJUI 103 2009 883 888
26. M. Bolla, L. Collette, and L. Blank Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial Lancet 360 2002 103 108
27. P.S. Tofts, G. Brix, and D.L. Buckley Estimating kinetic parameters from dynamic contrast-enhanced T1-weighted MRI of a diffusable tracer: standardized quantities and symbols J Magn Reson Imaging 10 1999 223 232
28. K. Murase Efficient method for calculating kinetic parameters using T1-weighted dynamic contrast-enhanced magnetic resonance imaging Magn Reson Med 51 2004 858 862
29. A. Shukla-Dave, N. Lee, and H. Stambuk Average arterial input function for quantitative dynamic contrast enhanced magnetic resonance imaging of neck nodal metastases BMC Med Phys 9 2009 4
30. R. Meng, S.D. Chang, E.C. Jones, S.L. Goldenberg, and P. Kozlowski Comparison between population average and experimentally measured arterial input function in predicting biopsy results in prostate cancer Acad Radiol 17 2010 520 525
31. G.J.M. Parker, C. Roberts, and A. Macdonald Experimentally-derived functional form for a population-averaged high-temporal-resolution arterial input function for dynamic contrast-enhanced MRI Magn Reson Med 56 2006 993 1000
32. Y. Wang, W. Huang, D.M. Panicek, L.H. Schwartz, and J.A. Koutcher Feasibility of using limited-population-based arterial input function for pharmacokinetic modeling of osteosarcoma dynamic contrast-enhanced MRI data Magn Reson Med 59 2008 1183 1189
33. C.A. Woodfield, G.A. Tung, D.J. Grand, J.A. Pezzullo, J.T. Machan, and J.F. Renzulli Diffusion-weighted MRI of peripheral zone prostate cancer: comparison of tumor apparent diffusion coefficient with Gleason score and percentage of tumor on core biopsy Am J Roentgenol 194 2010 W316 W322
34. T. Tamada, T. Sone, and Y. Jo Apparent diffusion coefficient values in peripheral and transition zones of the prostate: comparison between normal and malignant prostatic tissues and correlation with histologic grade J Magn Reson Imaging 28 2008 720 726
35. K. Yoshimitsu, K. Kiyoshima, and H. Irie Usefulness of apparent diffusion coefficient map in diagnosing prostate carcinoma: correlation with stepwise histopathology J Magn Reson Imaging 27 2008 132 139